<DOC>
	<DOCNO>NCT02503137</DOCNO>
	<brief_summary>This study ass safety , tolerability , efficacy SM04554 concentration 0.15 % 0.25 % . Improved knowledge change hair count immunohistochemical analysis associate androgenetic alopecia ( AGA ) treatment SM04554 compare placebo may lead great understand underlying mechanisms action SM04554 .</brief_summary>
	<brief_title>A Study SM04554 Applied Topically Scalp Male Subjects With Androgenetic Alopecia Analyzed Biopsy Scalp Prior To Post Dosing</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Clinical diagnosis AGA NorwoodHamilton Classification score 4 , 5 , 5A , 5V , 6 In good general health , determine Investigator Willing able attend study visit Willing undergo two punch biopsy scalp Willing inform female , may interact , use topical investigational product direct contact avoid potential harm fetus unknown Willing use permanent semipermanent hair product ( e.g. , color , texturizers , relaxer ) duration study ; daily style product allow nonstudy visit day ( e.g. , hair gel , mousse , style spray ) Willing use sponsorsupplied shampoo conditioner place regular shampoo conditioner , duration study ; use sponsorsupplied conditioner optional subject use conditioner Clinical diagnosis alopecia areata nonAGA form alopecia Scalp hair loss treatment area , due disease , injury , medical therapy Males sexually active partner capable become pregnant , neither surgery become sterilize , use highly effective method birth control willing use highly effective method birth control study treatment period 90 day post last dose study medication Current skin disease ( e.g. , psoriasis , atopic dermatitis , eczema , sun damage , seborrheic dermatitis , actinic keratosis ) , cut and/or abrasion scalp hand condition ( e.g. , sunburn , tattoo ) treatment area hand , opinion Investigator , might put subject risk interfere study conduct evaluation History current skin cancer ( e.g. , melanoma , basal cell carcinoma , squamous cell carcinoma ) locate anywhere body History surgical correction hair loss scalp Previous exposure SM04554 Use blood thinner ( e.g. , Coumadin , Plavix , Lovenox , aspirin &gt; 81mg ) ; low dose aspirin ( e.g. , â‰¤81 mg ) allowable Use product device clinically proven promote scalp hair growth ( e.g. , finasteride minoxidil ) within 24 week prior study start Use antiandrogenic therapy ( e.g. , spironolactone , flutamide , cyproterone acetate , cimetidine ) within 12 week prior study start Use semipermanent hair product ( e.g. , color , texturizers , relaxer ) within 30 day prior study start Use medicate shampoo conditioner ( medicate shampoo conditioner refer prescription shampoo conditioner well overthecounter medicate shampoo conditioner , treatment dandruff promote hair growth ) within 30 day prior study start History hair transplant Current use occlusive wig , hair extension , hair weave Participation investigational drug medical device trial include administration investigational study medication medical device , within 30 day 5 halflives investigational agent , whichever longer , prior study start Poor peripheral venous access Subjects unwilling refrain sperm donation study treatment period 90 day post last dose study medication Subjects pregnant partner study start Subjects immediate family member ( spouse , parent , child , sibling ; biological legally adopt ) personnel directly affiliate study investigative site , directly affiliate study investigative site Subjects employ Samumed , LLC , affiliate development partner ( , employee , temporary contract worker , designee ) responsible conduct study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>male pattern baldness</keyword>
	<keyword>SM04554</keyword>
	<keyword>AGA</keyword>
</DOC>